Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection

Steven S Yu
David I Quinn
Tanya B Dorff
Division of Oncology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA

Abstract: Clear cell (cc) renal cell carcinoma (RCC) is the most common type of cancer found in the kidney accounting for ~90% of all kidney cancers. In 2012, there were ~337,000 new cases of RCC diagnosed worldwide with an estimated 143,000 deaths, with the highest incidence and mortality in Western countries. Despite improvements in cancer control achieved with VEGF- and mTOR-targeted therapy for RCC, progression remains virtually universal and additional therapies are needed. The pivotal results of the METEOR trial led to cabozantinib’s designation as a breakthrough drug by the US Food and Drug Administration and its approval for treatment of advanced RCC in 2016. Subsequent data from the CABOSUN trial, where cabozantinib is compared with sunitinib, will provide information on the relative activity of cabozantinib as first-line therapy for ccRCC. We review the development of cabozantinib in advanced RCC and its role in the treatment landscape for advanced RCC.

Keywords: cabozantinib, renal cell carcinoma, kidney cancer, clear cell carcinoma, tyrosine kinase inhibitor

Introduction
Clear cell (cc) renal cell carcinoma (RCC) is the most common type of cancer found in the kidney accounting for ~90% of all kidney cancers. In 2012, there were ~337,000 new cases of RCC diagnosed worldwide with an estimated 143,000 deaths, with the highest incidence and mortality in North America and Europe. The USA is among the top four countries in incidence and mortality worldwide. The development of RCC is associated with smoking, obesity, male sex, and family history and genetic conditions such as von Hippel-Lindau disease as well as possibly type 2 diabetes mellitus and hepatitis C infection. In the USA, there were an estimated 62,000 new cases and ~14,000 deaths from RCC in 2015. Patients with localized disease have a nearly 92% 5-year survival with curative surgery, whereas patients with advanced RCC have 5-year survival rates of ~11%–12%. Despite improvements in cancer control achieved with VEGF- and mTOR-targeted therapy for RCC, progression remains virtually universal and additional therapies are needed. In this review, we delineate the differences between cabozantinib and preexisting VEGF-targeted therapy by reviewing the efficacy, safety, and patients who benefit from cabozantinib. We assess the quality of preclinical data and Phases I–III trials testing cabozantinib in various cancer types and identify gaps in knowledge where new trials are needed.
Methods

For the elements related to cabozantinib use in renal cell cancer for this review, we undertook a systematic assessment of literature and peer-reviewed presentations by searching PubMed, MEDLINE, and major oncology meeting (ASCO.org, ESMO.org, and ECCO.org) abstracts. The following keywords were used in the database searches: (cabozantinib or cabozantinib-s-malate or RTK inhibitor or XL 184 or tyrosine kinase inhibitor or TKI or multi-TKI) and (c-MET or MET or VEGFR or VEGFR2 or AXL or RET) and (renal cell carcinoma or kidney cancer or clear cell renal carcinoma or renal cancer) and (tumor growth or angiogenesis). Hits were confirmed as having full text or full presentation content that was accessible and vetted by the authors for relevance to the review. Content was then tabulated and summarized for use in the review. Study design, sample size, treatment effect, and adverse effects were reviewed by the three authors. The search included preclinical studies and human studies. Publications not primarily published in English were excluded.

Current therapies in advanced RCC

Prior to 2005, high-dose interleukin-2 and interferon alpha (IFNα) were the only approved treatments for advanced or metastatic RCC disease with ~5% of patients achieving a complete response. However, the use of high-dose interleukin-2 is limited to relatively young, healthy patients and restricted to administration in centers with experience in managing the considerable toxicities of the regimen. With the recognition of the biologic basis of RCC due to loss of the von Hippel Lindau (VHL) tumor suppression of angiogenic pathways, therapeutic development focused on targeting vascular endothelial growth factor (VEGF) and mTOR pathways. The first agents to be approved were multitargeted receptor tyrosine kinase inhibitors (TKIs). Currently, the US Food and Drug Administration (FDA) approved the following five VEGF pathway inhibitors in metastatic RCC: bevacizumab, sunitinib, sorafenib, pazopanib, and axitinib. The inhibition of the VEGF/VEGFR pathway by these drugs has moved the overall survival in metastatic RCC to a median of 2 years in the first-line setting. In addition to targeting the VEGF receptor, these agents inhibit a variety of receptors including PDGF and c-kit.

While these TKIs significantly prolonged progression-free survival (PFS) compared to IFNα in previously untreated patients with advanced or metastatic RCC, issues including toxicity led to further development of additional agents such as axitinib and pazopanib. Axitinib is highly selective for the inhibition of VEGFR-1, VEGFR-2, and VEGFR-3 and was approved by the FDA for progressive disease after one “first-line” therapy based largely on the AXIS trial.12 A Phase III randomized trial, the AXIS trial, randomized 723 patients with metastatic RCC to axitinib or sorafenib after failure of first-line therapy and demonstrated that axitinib had significantly longer PFS than sorafenib (6.7 vs 4.7 months; hazard ratio [HR] 0.665; 95% CI 0.544–0.812; P<0.0001). However, no overall survival benefit was observed. In a Phase III trial with 435 patients, pazopanib, another VEGF, PDGF, and Kit inhibitor, doubled the PFS but had no improvement in OS in locally advanced or metastatic disease when compared with placebo.13 When compared with sunitinib head-to-head in the COMPARZ trial, there was no difference in PFS or OS.14 An alternative approach to suppressing VEGF signaling was to target the ligand with bevacizumab, a monoclonal antibody that binds to circulating VEGF and prevents it from activating the VEGF receptor. This strategy was also successful with prolonged PFS in combination with interferon compared to IFNα alone in the AVOREN and CALGB trials, leading to FDA approval for its use in RCC.15,16 The mTOR pathway plays a central role in the regulation of cell growth, influencing many critical molecular functions, including angiogenesis, cell proliferation, and glucose homeostasis. mTOR signaling is upregulated in RCC, making it an attractive therapeutic target.17 The following two agents were developed based on their ability to inhibit mTOR signaling: temsirolimus, an intravenous preparation administered weekly, and everolimus, an oral analog of rapamycin. A Phase III trial led to the approval of temsirolimus for previously untreated, poor-risk RCC. Six hundred twenty-six previously untreated patients were randomly assigned to temsirolimus, temsirolimus + IFNα, or IFNα monotherapy. Temsirolimus significantly prolonged the median overall survival compared to IFNα as a single agent (10.9 vs 7.3 months, HR 0.73, 95% CI 0.58–0.92).18 However, in VEGF-pretreated patients, temsirolimus demonstrated a shorter overall survival than sorafenib in 512 patients who had progressed on sunitinib.19 On the other hand, everolimus initially was approved based on its efficacy in VEGF-pretreated patients. In the RECORD-1 trial, a double blind, randomized, placebo-controlled Phase III trial, everolimus demonstrated PFS superiority over placebo in patients with metastatic RCC progressing on VEGF TKIs. A total of 416 patients were randomized to either everolimus or placebo, resulting in a median PFS of 4.9 months in the everolimus group vs 1.9 months in the placebo group.20
VEGF and MET in RCC

VEGF

Angiogenesis involves the formation of new blood vessels from the preexisting blood vessels and is one of the hallmarks of cancer. Neoangiogenesis supplies the tumor with nutrients for progression and invasion into surrounding tissue and contributes to lymphatic invasion and distant metastasis. The process is controlled by growth factors such as vascular endothelial growth factor, fibroblast growth factor, hepatocyte growth factor, insulin-like growth factor, and transcription factors such as hypoxia inducible factor to increase endothelial cell proliferation, migration, and survival (Figure 1).

In the majority of renal cell cancer, the VHL is inactivated causing upregulation of VEGF and other factors. VEGF stimulates the endothelial cells, which form the walls of the vessels and help in maintaining the transport of oxygen and nutrients to the tissues, hence promoting growth. The upregulation of VEGF leads to an increased angiogenesis, endothelial permeability, and tumor cell viability and a more invasive tumor phenotype. Therapy with agents directed against the VEGF protein or the VEGF receptor is a central basis of current treatments with today’s antiangiogenic drugs.

Within the VEGF family of glycoproteins, there are VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placental growth factors, each involved in angiogenesis and formation of other vessels. Each glycoprotein is activated by binding to an extracellular tyrosine kinase receptor on the cell surface called VEGFR-1, VEGFR-2, and VEGFR-3. These receptors dimerize and phosphorylate, activating the cellular responses exhibited by VEGF glycoproteins. VEGFR-2 is hypothesized to mediate all the cellular functions of VEGF, and VEGFR-1 seems to modulate the function of VEGFR-2, although its exact function is not defined. The most important glycoprotein in the VEGF family is VEGF-A. This ligand is particularly important because it has a dramatic upregulation of its expression levels under hypoxic conditions. During hypoxic conditions, hypoxia inducible factor is stabilized, binding to specific promoter elements, which are present in the promoter region of VEGF-A. This activated VEGF-A gets bound to the VEGFR, mostly with VEGFR-2, inducing angiogenesis. In preclinical models, targeting the VEGF signaling pathway has proven to be efficacious, inhibiting neovascularization and yielding tumor regression in animal models.27

Figure 1 Angiogenesis is controlled by growth factors such as vascular endothelial growth factor and hepatocyte growth factor, which increase endothelial cell proliferation, migration, and survival.

Note: Adapted with permission from Exelisix, Inc. © 2016.25
Targeting the VEGF has been a very successful strategy for treating metastatic RCC. However, suppression of VEGF signaling is not universally effective; there are patients with primary refractory disease as well as nearly universal acquired resistance. Redundancy in mechanisms for angiogenesis likely account for some resistance, including induction of the protooncogene called mesenchymal–epithelial transition (MET) factor. VEGF and MET are overexpressed in hypoxic environments to promote survival by stimulating angiogenesis or facilitating migration away from the hypoxic zone (Figure 2). Inhibition of the VEGF pathway alone can induce hypoxemia and also trigger a compensatory upregulation of MET expression, which helps drive tumor invasion. Targeting the MET is the rational strategy to overcome VEGF-targeted therapy resistance.

**MET**

The MET signaling pathway is important in tumor growth, survival, and metastasis and acts synergistically with VEGF to promote angiogenesis. In mouse models, the hepatocyte growth factor–MET pathway plays a key role in bone metastasis development. In renal cancer cells, MET protects cells from apoptosis, increases invasion and motility, and fosters epithelial–mesenchymal transition. As demonstrated in animal models and preclinical studies, inhibition of VEGF alone without MET produces rapid progression of tumors. Preclinical studies have shown that by blocking the VEGF pathway, hypoxia is induced, but the stress on the tumor cells results in a compensatory upregulation of MET expression, which further stimulates angiogenesis and migration away from the hypoxic zone. After inhibition of cellular receptors of VEGF that promote angiogenesis, tumor cells attempt to escape the hypoxic environment by metastasizing and seeking a more hospitable location. This rapid revascularization and subsequent metastasis is presaged by MET overexpression, leads to resistance of the VEGF pathway, and is a fundamental mechanism that tumor cells use to survive. In vivo studies of sunitinib, the MET pathway was identified as important in the development of resistance to VEGF signaling inhibition. In the experimental model, flow cytometry showed that MET expression was higher in resistant tumor cells. Combining sunitinib with a selective MET inhibitor significantly enhanced tumor suppression when compared with sunitinib or MET inhibitor alone in resistant tumors.

The discovery that VEGFR and MET pathways work synergistically in tumor cells underlies the development of cabozantinib. Similar to other VEGF TKIs, cabozantinib inhibits vascular endothelial cell tubule formation in vitro, cellular migration, invasion, and tumor cell proliferation in a variety of tumor types. Uniquely, cabozantinib inhibits MET and VEGFR2 phosphorylation in vivo, preventing compensatory metastasis following intravenous tumor cell inoculation. By targeting both pathways simultaneously, cabozantinib blocks metastatic escape pathways and inhibits the expression of other potential resistance factors such as phosphatidylinositol-3-kinase, phospholipase C, pp60src, and Grb2/Sos1. Preclinical studies found that cabozantinib inhibited the appearance of liver metastasis in a transgenic mouse xenograft model. Treatment with cabozantinib resulted in a more extensive tumor shrinkage and a decreased tumor invasiveness and metastasis than treatment with vehicle or anti-VEGF antibody alone. The median survival

**Figure 2** VEGF, HIF1, and MET are upregulated in hypoxic environments to promote survival by stimulating angiogenesis or facilitating migration away from the hypoxic zone.

**Note:** Adapted with permission from Exelixis, Inc. © 2016.

**Abbreviations:** AR, androgen receptor; NSCLC, non-small cell lung cancer.
was 14.7 weeks for vehicle-treated animals and 16.4 weeks for anti-VEGF antibody-treated animals, while animals treated with MET inhibitors demonstrated an improved survival of >20 weeks ($P<0.05$). Of significance in the study, all of the mice treated with cabozantinib survived until the experiment ended at 20 weeks, whereas none of the vehicle- or anti-VEGF antibody-treated mice survived to that endpoint. This study suggests that dual inhibition of MET and VEGFR2 with cabozantinib is more effective and results in a more sustained response than inhibition of VEGF pathway alone.

**Role of cabozantinib**

In 2011, cabozantinib emerged as a new, orally bioavailable, small-molecule receptor TKI with dual VEGF and MET inhibition properties. Preclinical experiments found that inhibition of MET and VEGFR2 phosphorylation in vitro and in tumor models in vivo led to significant reductions in cell invasion. In vivo, the effect of disruption of tumor vasculature by cabozantinib was studied on antiangiogenic-sensitive tumor cells expressing MET and VEGF in animal models. The animals were divided into two groups in which one group was administered the drug with vehicle and the second group was administered only the drug. Both groups were administered the same dose orally, and after first 4 and 8 hours intervals, tumors were collected. Consecutive tumor collection was done after 4 hours interval following second, third, and fourth administrations of the drug. Cabozantinib-treated tumor cells exhibited ~13 times greater levels of tumor hypoxia and 2.5 times greater levels of apoptosis, measured by cell death marker TUNEL, after the first and second doses as compared to the vehicle-treated tumors. In mouse models, cabozantinib dramatically altered tumor pathology, resulting in decreased tumor and endothelial cell proliferation coupled with increased apoptosis and dose-dependent inhibition of tumor growth in various tumors. Cabozantinib was also found to bind to and inhibit other tyrosine kinases implicated in tumor pathobiology involved in angiogenesis including RET, KIT, AXL, and FLT3 (Figure 3).

A Phase I study was undertaken using cabozantinib in a dose de-escalation design beginning at 140 mg orally daily in 25 heavily pretreated patients with metastatic renal cell cancer. The most common clinical side effects were fatigue (80%), diarrhea (64%), anorexia (36%), and vomiting (36%). Common grade ≥3 adverse events included fatigue (20%), diarrhea (12%), pulmonary embolism (12%), hypophosphatemia (40%), proteinuria (8%), appetite decreased (4%), palmar-plantar erythrodysesthesia (4%), and vomiting (4%). Dose reductions occurred in 20 of the 25 patients: the final daily dose was 100 mg for 6 patients, 60 mg for 11 patients, 40 mg for 2 patients, and 20 mg for 1 patient. The median average daily dose was 75.5 mg. Of the 21 subjects assessable for radiological response by RECIST, partial response was reported in 7 patients (28%) while 13 patients (52%) had stable disease and only 1 patient had progressive disease as the best response. The median PFS was 12.9 months, and the median overall survival was 15.0 months. At the conclusion of this trial, it was clear that cabozantinib promised significant efficacy compared to historical controls for cancer control and PFS and overall survival. Questions remained regarding toxicity; therefore, the optimal dose in renal cell cancer was decided based on experiences in other solid tumor studies.

With robust Phase I evidence of cabozantinib activity in RCC, researchers embarked on a phase III trial, known as the METEOR trial, without conducting intercurrent Phase II trials. The METEOR trial compared cabozantinib with everolimus in 658 patients with RCC who had experienced disease progression following treatment with a VEGF receptor

---

**Figure 3** Cabozantinib binds to and inhibits tyrosine kinases implicated in tumor pathobiology involved in angiogenesis including VEGF, MET, and AXL to block motility, invasion, metastasis, and angiogenesis.

**Note:** Adapted with permission from Exelixis, Inc. © 2016.

**Abbreviation:** TKIs, tyrosine kinase inhibitors.
TKI. Patient selection required histological or cytological diagnosis of renal cell cancer with a clear-cell component, measurable disease, recovery from prior toxicities related to any prior treatments. 658 patients were randomized in a 1:1 ratio to receive cabozantinib at a starting dose of 60 mg daily (330 patients) or everolimus (328 patients). The median age of patients was ~62 years (range, 31–86 years). All patients had received at least one prior VEGFR-targeted TKI and had radiographic progression within 6 months after the most recent dose. Previous systemic therapy primarily consisted of sunitinib (62%), pazopanib (43%), and axitinib (16%). The primary endpoint of PFS was assessed on the first 375 patients enrolled in the trial. In this portion of the study, 187 patients were randomized to cabozantinib and 188 received everolimus. The median PFS almost doubled from 3.8 months (95% CI 3.7–5.4) with everolimus to 7.4 months (95% CI: 5.6–9.1) with cabozantinib, representing a 42% reduction in the risk of progression or death (P<0.001). Cabozantinib was superior to everolimus for PFS across all subgroups. Objective tumor responses were observed in 21% of the cabozantinib group compared to 5% of patients treated with everolimus. When further assessed by an independent radiology process, the median PFS across all enrolled patients was 7.4 months for the cabozantinib arm vs 3.9 months for the everolimus arm, corresponding to a 48% reduction in the rate of disease progression or death for cabozantinib as compared to everolimus (HR =0.52, 95% CI 0.43–0.64, P<0.001). The objective response rate was 17% for cabozantinib and 3% for everolimus. In the secondary endpoint of the trial, the entire study population of 658 patients showed a median overall survival of 21.4 months (95% CI: 18.7–not estimable) with cabozantinib and 16.5 months (95% CI: 14.7–18.8) with everolimus (HR=0.66, 95% CI 0.53–0.83; P=0.00026). The pivotal results of the METEOR trial led to the approval of cabozantinib by the FDA for the treatment of advanced RCC in 2016.

**Dosing and toxicity**

**140 mg**

Initial studies showed that cabozantinib inhibits tumor growth in a dose-dependent manner, and dose escalation was evaluated. The maximum tolerated dose in the Phase I study specifically in medullary thyroid cancer patients was 175 mg daily with dose-limiting grade 3 or worse toxicities including fatigue (10%), elevation of lipase (9%), and amylase (5%), as well as diarrhea, weight loss, and transaminitis. For medullary thyroid cancer, a dose of 140 mg daily was chosen for the registration trial and became the FDA-approved dose for this indication.

A follow-up Phase III trial, EXAM, demonstrated substantial PFS prolongation with cabozantinib vs placebo in patients with medullary thyroid cancer. A total of 330 patients were administered cabozantinib in a 2:1 ratio either in 140 mg base form (219 patients) or placebo (111 patients). The most common grade 3/4 adverse events were diarrhea (cabozantinib 15.9% vs placebo 1.8%), hand–foot syndrome (cabozantinib 12.6% vs placebo 0%), fatigue (cabozantinib 9.3% vs placebo 2.8%), hypocalcemia (cabozantinib 9.3% vs placebo 0%), and hypertension (cabozantinib 7.9% vs placebo 0%). Notably, dose reductions occurred in 79% of patients and dose interruptions occurred in 65% patients in the cabozantinib arm. As a result of adverse events, 16% of patients treated with cabozantinib had the drug discontinued. The need for monitoring the adverse events on cabozantinib is supported by a recent meta-analysis of 22 publications looking at response and toxicity of TKIs in patients with thyroid carcinoma. In this meta-analysis, cabozantinib at 140 mg was found to be associated with the highest percentage of dose reductions and/or discontinuation among TKIs.

Based on dosing used to treat medullary thyroid cancer, a Phase I trial on RCC was conducted with a dose of 140 mg of cabozantinib daily. The trial showed encouraging efficacy but considerable toxicity as previously mentioned. Comparable to the medullary thyroid cancer studies, treatment discontinuation occurred in 24% of patients due to adverse events. Dose reductions occurred in 80% of patients. The median average daily dose was 75.5 mg cabozantinib (range, 43.8–137.5 mg), and the median dose intensity percentage was 53.9% (range, 31.3%–98.2%).

**100 mg**

Due to the high toxicities seen in the 140 mg dose of cabozantinib, subsequent Phase II trials were conducted on lower doses of cabozantinib in other tumor types, including metastatic prostate cancer. In a Phase II randomized discontinuation study, 171 patients with metastatic castrate-resistant prostate cancer received cabozantinib 100 mg daily: 68% of them had partial or complete resolution of bone scans and 67% of patients with pain at baseline reported a decrease in pain. However, by week 12, dose reductions occurred in 51% of patients, with 12% discontinuing treatment due to adverse events. The most common grade 3 toxicities were fatigue, hypertension, and hand–foot syndrome. The most common serious adverse event was pulmonary embolism (6%). A follow-up study with 144 patients with metastatic prostate cancer investigated cabozantinib at daily starting doses of 100 vs 40 mg until disease progression or...
unacceptable toxicity. Though there was bone scan response and clinically meaningful pain relief in the majority of patients, in the 100 mg cohort, 84% of patients had at least one dose reduction and 25% discontinued treatment because of an adverse event. In the 40 mg cohort, 31% of patients had at least one dose reduction because of an adverse event and 18% of them discontinued treatment. Interestingly, the median average daily dose received in the 100 mg and 40 mg cohorts was 55 and 36 mg/d, respectively. As a result, the starting doses of 100 mg were thought to be advisable for follow-up studies due to tolerability concerns while having equivalent efficacy as the true difference in actual dose administered between the cohorts was not large.

60 mg

Subsequent studies in prostate cancer, the COMET program, utilized 60 mg as the starting dose. Phase II studies conducted on lower doses of 60 and 40 mg of cabozantinib resulted in less adverse events and continued clinical efficacy. COMET 1 and 2 were randomized, double blind, controlled trials completed for metastatic castrate-resistant prostate cancer at a starting dose of cabozantinib of 60 mg daily. Sixty percent of patients who received cabozantinib experienced at least one dose reduction. COMET 2 compared cabozantinib with mitoaxantrone and prednisone (MP): 55% of the patients receiving cabozantinib experienced at least one dose reduction compared to 14% of the patients receiving MP. Seventy percent of the patients in the cabozantinib group had a grade 3/4 adverse event. However, fewer patients discontinued study treatment for adverse events in the cabozantinib arm (16% vs 26% for MP).

In the METEOR trial, the 60 mg cabozantinib dose was used as the starting dose; notably dose reductions were still required in 60% of patients in the cabozantinib arm, most commonly due to diarrhea, plantar palmar dysesthesia, hypertension, and fatigue. The median average daily dose was 44 mg for cabo znatinib and 9 mg for everolimus. Serious adverse events occurred equally in both the cabozantinib and everolimus groups (40% and 43%, respectively). Treatment discontinuation because of an adverse event not related to disease progression was recorded in 40 (12%) of 331 patients in the cabozantinib group and 34 (11%) of 322 patients in the everolimus group (Table 1). Death considered related to study treatment occurred in one patient in the cabozantinib group (death not otherwise specified) and in two patients in the everolimus group (aspergillosis and aspiration pneumonia).

Importantly, cabozantinib at lower doses continues to have clinical efficacy, especially in medullary thyroid cancer and RCC with much improved tolerability. Previous meta-analysis showing cabozantinib to have a highest percentage of discontinuation among TKIs was studied with a starting dose of 140 mg much higher than the approved 60 mg dose in RCC. When comparing across trials, the 60 mg dose has a similar discontinuation rate to sorafenib, which is lower than other TKIs (Table 2). The median average daily dose in the METEOR trial was 43 mg for cabozantinib and suggests that the toxicity threshold may be slightly >40 mg rather than the starting dose of 60 mg. Analysis of the CABOSUN study, where cabozantinib is being compared with sunitinib for previously untreated patients with advanced intermediate- or poor-risk RCC renal cancer, will provide more data on comparative toxicity and tolerability and also raise the possibility

### Table 1 Summary features of the METEOR trial

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Rates of dose reduction</th>
<th>Median average daily dose (mg)</th>
<th>Rate of discontinuation</th>
<th>Grade 3/4 adverse events</th>
<th>ORR</th>
<th>Median PFS (months)</th>
<th>OS (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cabozantinib N=331</td>
<td>60% (197)</td>
<td>44</td>
<td>12% (40)</td>
<td>68% (226)</td>
<td>21% (40)</td>
<td>7.4</td>
<td>21.4</td>
</tr>
<tr>
<td>Everolimus N=322</td>
<td>25% (79)</td>
<td>9</td>
<td>11% (34)</td>
<td>58% (187)</td>
<td>5% (9)</td>
<td>3.8</td>
<td>16.5</td>
</tr>
</tbody>
</table>

**Notes:** The rate of treatment discontinuation due to adverse events not related to renal cell carcinoma in the cabozantinib group and in the everolimus group. *Among the first 375 patients who underwent randomization 187 patients assigned to cabozantinib and 188 patients assigned to everolimus. Data from Choueiri et al.*

**Abbreviations:** PFS, progression-free survival; ORR, overall response rate; OS, overall survival.

### Table 2 Summary of selected Phase iii trials of advanced RCC therapeutics and dose discontinuations due to adverse events

<table>
<thead>
<tr>
<th>Trial</th>
<th>Systemic therapy</th>
<th>N</th>
<th>Dose discontinuation (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rini et al ¹²</td>
<td>Sorafenib</td>
<td>355</td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>Axitinib</td>
<td>359</td>
<td>4</td>
</tr>
<tr>
<td>Sternberg et al ¹³</td>
<td>Pazopanib</td>
<td>290</td>
<td>14</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>145</td>
<td>3</td>
</tr>
<tr>
<td>Motzer et al ¹⁴</td>
<td>Pazopanib</td>
<td>554</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td>Sunitinib</td>
<td>548</td>
<td>20</td>
</tr>
<tr>
<td>Choueiri et al ¹⁵</td>
<td>Cabozantinib</td>
<td>331</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>Everolimus</td>
<td>322</td>
<td>11</td>
</tr>
<tr>
<td>Motzer et al ¹⁶</td>
<td>Nivolumab</td>
<td>406</td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>Everolimus</td>
<td>397</td>
<td>13</td>
</tr>
<tr>
<td>Hudes et al ¹⁷</td>
<td>Temsirolimus</td>
<td>209</td>
<td>15</td>
</tr>
<tr>
<td></td>
<td>Interferon alpha</td>
<td>207</td>
<td>29</td>
</tr>
</tbody>
</table>

**Abbreviation:** RCC, renal cell carcinoma.
of its use as a first-line drug. This trial and other ongoing trials are summarized in Table 3.

**Dose equivalence**

While cabozantinib in capsule formulation was approved for the treatment of medullary thyroid cancer (Cometiq), cabozantinib was reformulated into tablets with greater bioavailability, and this formulation (Cabometyx) was tested in the METEOR trial. When studying pharmacokinetics of cabozantinib tablet and capsule formulations in healthy adults, there are slight differences. A Phase I, randomized, open-label single-dose study in healthy individuals characterized the plasma pharmacokinetics of cabozantinib capsule, and tablet formulations showed a 19% increase in the Cmax of the tablet formulation compared to the capsule formulation following a single 140 mg dose. However, a <10% difference in the AUC was observed between cabozantinib tablet and capsule formulations. Thus, in pharmacokinetic studies, the tablet and capsule formulations failed to fulfill the bioequivalence study acceptance criteria. Though not a large difference in pharmacokinetic activity, the results suggest that patients with RCC should only be given the tablet form (Cabometyx) to ensure more accurate monitoring and the tablet form is not interchangeable with the capsule form.

**Discussion**

The advent of VEGF and mTOR inhibitors in RCC has significantly improved the prognosis for patients with metastatic RCC. In patients not eligible for IFNα or interleukin-2, VEGF TKIs have replaced cytokines as the standard of care in metastatic RCC. However, complete responses are rare (3%), and identifying agents effective in the setting of de novo or acquired resistance remains an important goal. The METEOR trial established cabozantinib as a choice for treatment in the second line and beyond, validating the preclinical work suggesting that MET acts as an alternative angiogenic pathway in the development of VEGF TKI resistance (Figure 4). As yet there are no known biomarkers to help with selection of patients for whom cabozantinib will be most effective; this has remained an elusive goal throughout the RCC therapeutic landscape.

Toxicity remains an important concern in the management of metastatic RCC, especially as more effective treatments result in longer durations of therapy. A meta-analysis recently drew attention to the high incidence and increased risk of developing hand–foot syndrome with cabozantinib, possibly in a dose-dependent manner. When comparing across trials, the approved starting dose of cabozantinib has similar and even less discontinuation due to adverse events compared to other TKIs. Proactive and aggressive management of this toxicity and others will be critical for maintaining the quality of life for RCC patients on cabozantinib. Dose reductions and discontinuations for the aforementioned trials are summarized in Tables 2 and 4.

**Future directions**

Further studies are needed to delineate the optimal cabozantinib dose. Patients should be counseled on its toxicity profile prior to treatment. As clinicians, we may need to reassess current dosing strategies and can look at other TKIs for prospective adjustments in dosing. A 2 weeks-on and 1 week-off schedule of sunitinib has shown decreased toxicity in metastatic RCC patients who initially experience grade ≥3 toxicity on the 4/2 schedule and a 2/1 schedule can extend treatment duration considerably. In the RAINBOW trial, a large retrospective analysis of 208 patients found that switching sunitinib to an alternate 2 weeks on and 1 week off schedule without affecting dose density over a 6-week cycle was associated with improved outcomes and increased...
tolerability. The 2/1 schedule reduced overall incidence of grade 3–4 toxicities to 8.2% compared to 45.7% in the 4/2 schedule in the same patients and 29.4% in the control arm. Other studies have shown a lower incidence of dose interruption and similar outcomes compared with the standard dosing schedule of 4 weeks on and 2 weeks off.

The sequence that cabozantinib should be used among the growing number of therapeutic options is also up for investigation. Though cabozantinib’s approval was based on patients with advanced RCC who had received prior anti-angiogenic therapy, there may be a role for the drug in treatment-naïve patients as a first-line therapy. The Phase II CABOSUN study will compare cabozantinib to a 4/2 schedule of sunitinib in the first-line setting and compare the tolerability of these regimens. Patients were randomized in a 1:1 ratio to 60 mg once daily of cabozantinib or 50 mg once daily (4 weeks on and 2 weeks off) of sunitinib with the primary outcome measured as PFS and OS, with the secondary endpoints including objective response rate. If the safety profile is similar to previously reported studies and shows improved PFS, OS, or ORR when compared with sunitinib, then cabozantinib could prove to be the new standard first-line therapy for untreated advanced RCC.

In the second-line setting, cabozantinib is considered a standard of care therapy in patients who have received prior antiangiogenic therapy. Similar to other TKIs, cabozantinib can be given safely with careful adverse-event monitoring and appropriate dose reductions.

In addition to cabozantinib, nivolumab is an anti-PD-1 antibody newly approved as a second-line option for

---

**Table 4** Summary of trial dose reductions and discontinuations

<table>
<thead>
<tr>
<th>Trial</th>
<th>Cancer type</th>
<th>Cabozantinib dose (mg)</th>
<th>N</th>
<th>Dose reduction (%)</th>
<th>Dose discontinuation (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Choueiri et al[2]</td>
<td>RCC</td>
<td>140</td>
<td>25</td>
<td>80</td>
<td>24</td>
</tr>
<tr>
<td>Schoffski et al[19] (EXAM)</td>
<td>MTC</td>
<td>140</td>
<td>219</td>
<td>79</td>
<td>16</td>
</tr>
<tr>
<td>Smith et al[1]</td>
<td>Prostate Ca</td>
<td>100</td>
<td>171</td>
<td>51</td>
<td>12</td>
</tr>
<tr>
<td>Leibowitz-Amitt et al[2]</td>
<td>Prostate Ca</td>
<td>100</td>
<td>93</td>
<td>84</td>
<td>25</td>
</tr>
<tr>
<td></td>
<td></td>
<td>40</td>
<td>51</td>
<td>31</td>
<td>18</td>
</tr>
<tr>
<td>Smith et al[26] (COMET 1)</td>
<td>Prostate Ca</td>
<td>60</td>
<td>682</td>
<td>67</td>
<td>33</td>
</tr>
<tr>
<td>Basch et al[17] (COMET 2)</td>
<td>Prostate</td>
<td>60</td>
<td>61</td>
<td>55</td>
<td>16</td>
</tr>
<tr>
<td>Choueiri et al[28] (METEOR)</td>
<td>RCC</td>
<td>60</td>
<td>331</td>
<td>62</td>
<td>12</td>
</tr>
</tbody>
</table>

**Abbreviations:** MTC, medullary thyroid cancer; RCC, renal cell carcinoma.
metastatic RCC. Currently, there are no trials comparing cabozantinib with nivolumab, but an ongoing combination trial could prove to be beneficial. Nivolumab is an anti-PD-1 antibody that was initially developed for patients with advanced melanoma and non-small-cell lung cancer and has shown activity in advanced RCC. In a large Phase III trial, Checkmate-025, nivolumab prolonged overall survival when compared with everolimus as a second-line therapy in patients progressing after initial treatment with a VEGF TKI. The toxicity profile was notably low with grade 3 or 4 treatment-related adverse events occurring in only 19% of patients receiving nivolumab. Nivolumab competes with cabozantinib after progression on first-line agents or for patients unable to tolerate cabozantinib. While these drugs have distinct mechanisms of action, the combination of cabozantinib and nivolumab may also lead to a potential benefit of immune modulation in genitourinary tumors. In a study of metastatic urothelial cancer, regulatory T cell levels prior to cabozantinib treatment have been shown predictive of therapeutic responsiveness and overall survival. When assessing myeloid-derived suppressor cells and regulatory T cells in patients undergoing treatment with cabozantinib after 2 cycles, patients with low regulatory T cells measured in peripheral blood samples at baseline had an improved response rate, PFS, and OS. Regulatory T cells decreased and PD-1 expression in regulatory T cells increased after cabozantinib treatment ($P=0.015$ and $P=0.011$, respectively). Patients with less change in PD-1 levels showed a trend to an improved PFS, and a decrease in myeloid-derived suppressor cells’ expression on treatment was associated with an improved PFS. These results suggest that changes in regulatory T cell checkpoint molecule expression and myeloid-derived suppressor cells expression may be prognostic and/or predictive markers in patients with metastatic urothelial carcinoma treated with cabozantinib. Such results have led to investigation of a Phase I trial of cabozantinib and nivolumab with or without ipilimumab in treating patients with genitourinary tumors (NCT02496208). Currently, there are no other cabozantinib-based combination therapies under trial but this remains a tantalizing area of investigation.

Cabozantinib should also be compared with other second-line agents approved for RCC. Cabozantinib has yet to be compared with axitinib in clinical trials, and given that both agents are now approved in the second-line setting, this would have merit. Cabozantinib should also be compared with the combination of levatinib + everolimus, which recently was shown to be superior to everolimus alone. An ongoing randomized Phase II trial comparing PFS with cabozantinib, crizotinib, volitinib, or sunitinib in metastatic papillary RCC will provide efficacy and toxicity data.

There may also be a role of cabozantinib in the adjuvant setting. The ASSURE trial looked at 1,943 patients with resected, intermediate- or high-risk kidney cancer (both clear cell and nonclear cell) and randomly assigned them to 1 year of adjuvant sorafenib, sunitinib, or placebo. There were no significant differences in disease-free survival or overall survival between the drug and placebo arm. The median disease-free survival was 5.8 years in both the sorafenib and sunitinib arms and 6 years in the placebo arm. Though these results suggest a lack of benefit of TKIs in the adjuvant setting, the ongoing SORCE, S-TRAC, and ATLAS trials investigate the use of adjuvant sorafenib and axitinib for 3 years, respectively. If these studies prove positive, it raises the possibility that cabozantinib could also be beneficial in the adjuvant setting after surgery, radiofrequency ablation, or cryoablation.

Currently, there are no biomarkers related to cabozantinib in RCC, but such a discovery might improve the utility of cabozantinib. In prostate cancer, cabozantinib had some activity in reducing circulating tumor cells and bone biomarkers on treatment, but the drug did not impact PSA in the Phase III COMET 1 study. In an analysis of a Phase II trial, plasma concentrations of VEGFR2, Trap5b, Angiopoietin-2, TIMP-2, and TIE-2 significantly decreased during treatment with cabozantinib; there was no significant associations between any biomarker and type of response. Carbozan
tinib also inhibits RET, ROS1, NTRK, MET, and AXL, and there may be utility in investigating its role in specific cancer genotypes. A Phase II study in patients with advanced non-small cell lung cancer is currently investigating cabozantinib in patients whose tumors express changes in RET, ROS1, or NTRK fusion or increased MET or AXL activity. In lung cancer, RET, ROS1, or NTRK fusion or increased MET or AXL activity gene leads to increased cell growth. If effective in non-small-cell lung cancer, similar studies with specific genotypes may be warranted in RCC. The MET pathway has been studied in papillary RCC with patients harboring a germline MET mutation showing high response rate in a Phase II study. Some patients with chromosome 7 and/or c-MET local alterations have also been shown to respond very well to pathway blockade, offering a potential area of investigation. In addition, cabozantinib has effects on immune markers and may counteract tumor-induced immunosuppression, providing a rationale for combining cabozantinib with immunotherapeutic strategies. In a study characterizing the pharmacodynamic effect of cabozantinib,
cabozenzintinib had an effect on PDL-1 and CTLA-4 expression on regulatory T cells, and T regulatory cell levels may be future prognostic markers.\textsuperscript{64} If such biomarkers could be validated in RCC and followed throughout treatment, it may facilitate dynamic targeted intervention in advanced RCC.

**Disclosure**

SSY declares that he has no relevant conflicts of interest that relate to the research described in this paper. DIQ declares that he has conflicts of interest including advisory board position and speaker honorarium with Pfizer, Bayer, Novartis, Exelixis, BMS, and Argos. TBD declares that she has conflicts of interest including speaker honorarium with Astellas, Bayer, Dendreon, Exelixis, Genentech, and Pfizer. The authors report no other conflicts of interest in this work.

**References**


57. Basch EM, Scholz MC, De Bono JS, et al. Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednison (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E). In: J Clin Oncol. 2015 Genitourinary Cancers Symposium; February 26–28, 2015. Orlando, Florida. 2015;33(Suppl 7), abstract 14.


